Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2013-02-14

FDA Approved: GONAL-F RFF REDI-JECT — Supplemental Application (EMD Serono, Inc.)

View source ↗

Summary

FDA approved a supplemental application for GONAL-F RFF REDI-JECT, a follitropin product for fertility treatment, submitted by EMD Serono, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GONAL-F RFF REDI-JECT (Follitropin)

Snippet

SUPPL AP for GONAL-F RFF REDI-JECT (FOLLITROPIN)